InsidersTradesSigma
Follow the MAIA Biotechnology, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, MAIA Biotechnology, Inc. has logged 106 insider filings. Market capitalisation: €80.9m. The latest transaction was disclosed on 1 September 2026 (Acquisition). Among the most active insiders: Smith Stan. The full history is free.
106
Insider Decl.
n/a
Thresholds
€5m
104 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate MAIA Biotechnology, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$12.00.
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 September 2026
Declarations106 total
78,239 shares@ US$1.390.13% mcap12.2% of flowCommon StockSEC:0001878313-26-000082:1
Canonical exit: 25 Nov 2026 (T+90)
8,931 shares@ US$1.390.015% mcap1.4% of flowCommon StockSEC:0001878313-26-000082:0
Canonical exit: 24 Nov 2026 (T+90)
46,620 shares@ US$1.350.078% mcap7.0% of flowCommon StockSEC:0001878313-26-000082:2
Canonical exit: 26 Nov 2026 (T+90)
1,794 shares@ US$1.330.0029% mcap0.3% of flowCommon StockSEC:0001878313-26-000079:0
Canonical exit: 22 Nov 2026 (T+90)
11,899 shares@ US$1.370.019% mcap2.3% of flowCommon StockSEC:0001878313-26-000077:0
Canonical exit: 18 Nov 2026 (T+90)
2,700 shares@ US$3.68840.4% of flowCommon StockSEC:0001878313-26-000021:0
Canonical exit: 18 Dec 2022 (T+90)
57,189 shares@ US$1.2242.4% of flowCommon StockSEC:0001878313-25-000073:0
Canonical exit: 22 Mar 2026 (T+90)
40,849 shares@ US$1.22427.5% of flowCommon StockSEC:0001878313-25-000071:0
Canonical exit: 22 Mar 2026 (T+90)
81,699 shares@ US$1.22417.1% of flowCommon StockSEC:0001878313-25-000069:0
Canonical exit: 22 Mar 2026 (T+90)
4,580 shares@ US$1.19970.2% of flowCommon StockSEC:0001878313-25-000063:0
Canonical exit: 5 Mar 2026 (T+90)
22,000 shares@ US$1.04630.026% mcap34.7% of flowCommon StockSEC:0001878313-25-000059:0
Canonical exit: 24 Feb 2026 (T+90)
10,500 shares@ US$0.96610.011% mcap15.3% of flowCommon StockSEC:0001878313-25-000060:0
Canonical exit: 23 Feb 2026 (T+90)
50,000 shares@ US$1.136626.9% of flowCommon StockSEC:0001878313-25-000056:0
Canonical exit: 26 Feb 2026 (T+90)
20,000 shares@ US$1.08089.5% of flowCommon StockSEC:0001878313-25-000054:0
Canonical exit: 24 Feb 2026 (T+90)
15,000 shares@ US$1.03880.6% of flowCommon StockSEC:0001878313-25-000052:0
Canonical exit: 24 Feb 2026 (T+90)
10,000 shares@ US$0.97854.3% of flowCommon StockSEC:0001878313-25-000050:0
Canonical exit: 23 Feb 2026 (T+90)
10,500 shares@ US$0.96614.8% of flowCommon StockSEC:0001878313-25-000047:0
Canonical exit: 23 Feb 2026 (T+90)
10,000 shares@ US$0.990.4% of flowCommon StockSEC:0001878313-25-000045:0
Canonical exit: 22 Feb 2026 (T+90)
1,800 shares@ US$0.921.2% of flowCommon StockSEC:0001878313-25-000040:0
Canonical exit: 19 Feb 2026 (T+90)
19,230 shares@ US$1.300.9% of flowCommon StockSEC:0001878313-25-000019:0
Canonical exit: 30 Dec 2025 (T+90)
33,333 shares@ US$1.501.8% of flowCommon StockSEC:0001127602-25-016869:0
Canonical exit: 1 Sept 2025 (T+90)
20,000 shares@ US$1.503.8% of flowCommon StockSEC:0001127602-25-013965:0
Canonical exit: 6 Aug 2025 (T+90)
66,666 shares@ US$1.503.8% of flowCommon StockSEC:0001127602-25-013963:0
Canonical exit: 6 Aug 2025 (T+90)
25,000 shares@ US$1.501.5% of flowCommon StockSEC:0001127602-25-008327:0
Canonical exit: 1 Jun 2025 (T+90)
33,333 shares@ US$1.506.9% of flowCommon StockSEC:0001127602-25-008330:0
Canonical exit: 1 Jun 2025 (T+90)
25 of 106 declarations
关于 MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. 是一家美国临床阶段生物制药公司，在美国纽约证券交易所美国市场 (NYSE) 上市。该公司成立于 2018 年，并于 2018 年 8 月在特拉华州注册成立，总部位于伊利诺伊州芝加哥，拥有一支分布式的团队，该团队还在美国其他地点和选定的国际地点远程运营。MAIA 尚未进入商业化阶段；它仍然是一家以研究为导向的肿瘤开发商，这意味着其投资概况是一家资本密集型小型生物技术公司，具有二元临床和融资里程碑。 公司的核心业务是开发靶向癌症疗法，由其旗舰研究资产 ateganosine（也称为 THIO 或 6-thio-dG）主导。Ateganosine 是一种一流的端粒靶向药物，旨在攻击端粒酶活性癌细胞，并与免疫检查点抑制剂联合使用。MAIA 主要专注于非小细胞肺癌 (NSCLC)，特别是晚期患者，这些患者已对先前的标准疗法失败。这使公司处于一个竞争激烈但科学差异化的免疫肿瘤学领域。其价值主张基于利基作用机制，而非广泛的平台多样化。 从临床开发的角度来看，MAIA 已使其主要项目通过多个关键阶段。公司获得了 THIO-101 的美国 IND 批准，在 2 期选择了开发剂量，并于 2025 年启动了关键的 3 期项目 THIO-104。2026 年，管理层表示，近期融资收益预计将为正在进行的关键试验提供全额资金。MAIA 还启动了其第一个美国 THIO-101 扩展站点，增加了已包括欧洲和澳大利亚的国际临床足迹。其他公司发展包括与罗氏的临床供应协议和反复的股权融资，这突显了公司对外部资本的依赖以执行其管线。 近期新闻流主要集中在临床进展和融资，而非商业执行。MAIA 宣布了 2026 年 3 月的承销公开发行，随后表示，收益加上之前的融资，应支持 3 期项目。公司还继续强调其端粒靶向差异化和非小细胞肺癌的早期疗效信号。对于投资者而言，主要机会在于新型肿瘤学机制的潜在临床验证；主要风险仍然是执行、稀释、监管不确定性和缺乏收入。简而言之，MAIA 是一个高风险、高回报的美国纽约证券交易所美国市场上市的生物技术故事，其估值几乎完全由临床数据读数和资金可见性驱动。
